Immunotherapies developer Scancell has launched a research programme focused on the development of a DNA vaccine candidate to protect from Covid-19.
The project will involve researchers from the University of Nottingham, Centre for Research on Global Virus Infections, the Biodiscovery Institute and Nottingham Trent University.
DNA vaccines by Scancell target dendritic cells to induce high avidity T-cells that identify and destroy diseased cells. The company’s lead candidate is an ImmunoBody cancer vaccine, SCIB1, which demonstrated safety and five-year survival in malignant melanoma patients in Phase I/II clinical trials.